Subscribe now

After decades of hope and hype, this year saw the coming of age of the “magic
bullet” approach to cancer. Glivec, the first “small molecule” cancer therapy,
got the fastest US approval of any cancer drug in history for treating a rare
leukaemia. It proved successful against a stomach cancer, too, and to complete a
busy year it has been granted a British licence. Glivec alone won’t be a miracle
cure for cancer. But with at least six other Glivec-like drugs in trials, each
aimed at a different kind of cancer, it won’t be long before doctors can tailor
treatments to each patient.

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up

To continue reading, subscribe today with our introductory offers

Popular articles

Trending New Scientist articles

Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop